BEDMINSTER, N.J., and DUBLIN, Ireland, July 2, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company focused on cardiovascular disease, announced today that the United States Patent and Trademark Office (USPTO) has published notification of a Notice of Allowance for U.S. Patent Application Serial Number 12/769,885 titled "Highly Stable EPA in a Capsule." A Notice of Allowance is issued after the USPTO makes a determination that a patent can be granted from an application. The issued patent would cover a stable pharmaceutical composition of AMR101 comprising at least 95% EPA and would have a patent term that would expire no earlier than in 2030.
